Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Royalty Pharma plc - Class A Ordinary Shares
(NQ:
RPRX
)
60.02
+1.02 (+1.74%)
Delayed Quote
Updated: 12:16 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Royalty Pharma plc - Class A Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Royalty Pharma PLC (NASDAQ:RPRX) Exceeds Q2 2025 Earnings Estimates and Raises Full-Year Guidance
↗
August 06, 2025
Royalty Pharma (RPRX) beats Q2 2025 earnings with $727M revenue, up 20% YoY, driven by key therapies. Shares rise as company raises full-year guidance, reinforcing growth confidence.
Via
Chartmill
Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates
August 06, 2025
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.8% year on year to $579 million. Its GAAP profit of $0.16 per...
Via
StockStory
Royalty Pharma Reports Second Quarter 2025 Results
August 06, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow
August 04, 2025
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be announcing earnings results this Wednesday before the bell. Here’s what to look for.
Via
StockStory
Topics
Government
World Trade
A Look Into Royalty Pharma Inc's Price Over Earnings
↗
June 23, 2025
Via
Benzinga
How Is The Market Feeling About Royalty Pharma?
↗
June 19, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
2 Reasons to Watch RPRX and 1 to Stay Cautious
July 30, 2025
Royalty Pharma has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.3%. The stock now trades at $36.72, marking a 16.2% gain. This was partly thanks to its...
Via
StockStory
Topics
Stocks
3 Profitable Stocks to Research Further
July 28, 2025
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting...
Via
StockStory
Topics
Supply Chain
Royalty Pharma Declares Third Quarter 2025 Dividend
July 18, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
July 17, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
July 16, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
↗
July 09, 2025
Via
Benzinga
2 Surging Stocks to Research Further and 1 to Be Wary Of
June 26, 2025
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...
Via
StockStory
Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds
↗
June 24, 2025
Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch.
Via
Benzinga
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma
↗
June 24, 2025
Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured...
Via
Stocktwits
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
June 24, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
June 18, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives
June 09, 2025
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $568.2 million. Its non-GAAP EPS of $1.06 per share was...
Via
StockStory
2 Value Stocks to Target This Week and 1 to Turn Down
June 06, 2025
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...
Via
StockStory
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
1 Stock Under $50 with Competitive Advantages and 2 to Question
June 04, 2025
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...
Via
StockStory
12 Health Care Stocks Moving In Friday's After-Market Session
↗
May 23, 2025
Via
Benzinga
Royalty Pharma Completes the Acquisition of Its External Manager
May 16, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
3 of Wall Street’s Favorite Stocks with Mounting Challenges
May 15, 2025
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...
Via
StockStory
Royalty Pharma to Present at Upcoming Investor Conferences
May 13, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
May 12, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates
May 08, 2025
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $568 million. Its GAAP profit of $0.75 per share...
Via
StockStory
Royalty Pharma Reports First Quarter 2025 Results
May 08, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
